Is NEXI or BTI a better dividend investment in 2026?

NEXI currently yields 666666.67% with a 5% 5-year dividend growth rate. BTI yields 5.38% with 5% growth. The better choice depends on your goal: NEXI offers higher current income.

What is the dividend yield difference between NEXI and BTI?

NEXI has a forward dividend yield of 666666.67% ($2.00/share annually). BTI yields 5.38% ($3.15/share annually). The yield gap is 666661.29 percentage points.

Home › Compare › NEXI vs BTI

NEXI vs BTI: Dividend Comparison 2026

NEXI yields 666666.67% · BTI yields 5.38%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NEXI wins by $8.275235618773884e+34M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NEXI

● Live price

666666.67%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.275235618773884e+34M

Annual income

$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00

Full NEXI calculator →

BTI

● Live price

5.38%

Share price

$58.47

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.7K

Annual income

$2,786.64

Full BTI calculator →

Portfolio growth — NEXI vs BTI

📍 NEXI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NEXI	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NEXI + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NEXI pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEXI

Annual income on $10K today (after 15% tax)

$56,666,666.67/yr

After 10yr DRIP, annual income (after tax)

$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr

BTI

Annual income on $10K today (after 15% tax)

$457.40/yr

After 10yr DRIP, annual income (after tax)

$2,368.64/yr

At 15% tax rate, NEXI beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEXI + BTI for your $10,000?

NEXI: 50%BTI: 50%

100% BTI50/50100% NEXI

Portfolio after 10yr

$4.137617809386942e+34M

Annual income

$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.97%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

NEXI

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$3.33

+1109900.0% upside vs current

Range: $2.00 — $5.00

Altman Z

-65.0

Piotroski

2/9

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.6% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEXI buys

BTI buys

No recent congressional trades found for NEXI or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNEXIBTI

Forward yield	666666.67% ✓	5.38%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$8.275235618773884e+34M	$37.7K ✓
Annual income after 10y	$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓	$2,786.64
Total dividends collected	$8.275075881065991e+34M	$14.3K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Buy	Buy
Analyst price target	$3.33	$40.00 ✓

Year-by-year: NEXI vs BTI ($10,000, DRIP)

Year	NEXI Portfolio	NEXI Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$66,677,367	$66,666,666.67	$11,299	$598.92	+$66.67M → NEXI
2	$415,506,651,117	$415,435,306,334.37	$12,794	$703.91	+$415506.64M → NEXI
3	$2,419,908,598,386,268	$2,419,464,006,269,573.00	$14,518	$829.07	+$2419908598.37M → NEXI
4	$13,171,697,643,084,456,000	$13,169,108,340,884,183,000.00	$16,513	$978.64	+$13171697643084.44M → NEXI
5	$67,004,927,492,790,120,000,000	$66,990,833,776,312,020,000,000.00	$18,827	$1,157.84	+$67004927492790120.00M → NEXI
6	$318,562,277,003,514,840,000,000,000	$318,490,581,731,097,560,000,000,000.00	$21,518	$1,373.12	+$318562277003514871808.00M → NEXI
7	$1,415,484,168,853,553,000,000,000,000,000	$1,415,143,307,217,159,200,000,000,000,000.00	$24,657	$1,632.46	+$1.415484168853553e+24M → NEXI
8	$5,878,130,573,362,507,000,000,000,000,000,000	$5,876,616,005,301,833,000,000,000,000,000,000.00	$28,329	$1,945.74	+$5.878130573362507e+27M → NEXI
9	$22,813,793,009,840,743,000,000,000,000,000,000,000	$22,807,503,410,127,248,000,000,000,000,000,000,000.00	$32,637	$2,325.33	+$2.2813793009840744e+31M → NEXI
10	$82,752,356,187,738,840,000,000,000,000,000,000,000,000	$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00	$37,708	$2,786.64	+$8.275235618773884e+34M → NEXI

NEXI vs BTI: Complete Analysis 2026

NEXI — Stock

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Full NEXI Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this NEXI vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEXI vs SCHD NEXI vs JEPI NEXI vs O NEXI vs KO NEXI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.